Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Theranostics|March 9, 2026
CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor modelSylvia T M Wenker, Mark W Konijnenberg, Daphne Lobeek, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 8, 2021
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatmentSteffie M B Peters, Regina Hofferber, Bastiaan M Privé, et al.
Theranostics|September 23, 2024
Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot studyNiels J van Ruitenbeek, Maike J M Uijen, Chantal M L Driessen, et al.
Ebiomedicine|March 22, 2024
Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging studyIlanah J Pruis, Pieter Jan van Doormaal, Rutger K Balvers, et al.
Theranostics|July 1, 2024
Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinomaSimone C Kleinendorst, Egbert Oosterwijk, Janneke Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2015
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical TherapyMichael Ljungberg, Anna Celler, Mark W Konijnenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot StudyBastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
Pageof 7